The company will invest more than $600m to facilitate a reliable supply of critical materials required for the production of new vaccines and biologics
Thermo Fisher Scientific has unveiled plans to invest more than $600m to expand its bioprocessing production capabilities through 2022.
With the investment, the company intends to increase its manufacturing capacity by more than double, and support biopharma customers.
The firm aims to meet both the short-term demands related to Covid-19, along with the development of new vaccines and biologics for other conditions.
Thermos Fisher said that the new investment will create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe and Asia.
Thermo Fisher Scientific executive vice president Michel Lagarde said: “As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials.
“Single-use technologies, cell culture media and purification resins are among those in highest demand.
“These investments add significant capacity and regional redundancy to further bolster supply chains and help us better support customers as they accelerate the commercialization of lifesaving therapies and vaccines.”
With the investment, the company will expand its single-use technologies to enhance the supply chain resiliency across multiple locations in the US, the UK, Singapore and China.
It is expected to expand the bioprocessing equipment and automation capacity at its Santa Clara, California site.
Thermo fisher would expand its advanced POROS resin manufacturing site in Bedford, and establish a new 85,000ft2 manufacturing facility in Chelmsford in Massachusetts.
The two sites are expected to strengthen the company’s purification network, which is specialised in the production of process-scale chromatography resins for different applications.
Also, the investment will help the company expand its capacity at Grand Island-New York, Miami-Florida and Inchinnan-Scotland sites.
The expansion will increase the production of Gibco cell culture media, supplements and process liquids, along with the manufacturing of customer-owned proprietary media formulations.
Thermo Fisher said that the investments will support the global supply and further extend its harmonising dual-milling capabilities.